174 related articles for article (PubMed ID: 8514401)
1. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.
Young BJ; Kozel TR
Infect Immun; 1993 Jul; 61(7):2966-72. PubMed ID: 8514401
[TBL] [Abstract][Full Text] [Related]
2. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans.
Kozel TR; Wilson MA; Welch WH
Infect Immun; 1992 Aug; 60(8):3122-7. PubMed ID: 1639481
[TBL] [Abstract][Full Text] [Related]
4. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.
Wilson MA; Kozel TR
Infect Immun; 1992 Mar; 60(3):754-61. PubMed ID: 1541548
[TBL] [Abstract][Full Text] [Related]
5. Differences in Cryptococcus neoformans capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces.
Washburn RG; Bryant-Varela BJ; Julian NC; Bennett JE
Mol Immunol; 1991; 28(4-5):465-70. PubMed ID: 2062324
[TBL] [Abstract][Full Text] [Related]
6. Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.
Kozel TR; deJong BC; Grinsell MM; MacGill RS; Wall KK
Infect Immun; 1998 Apr; 66(4):1538-46. PubMed ID: 9529079
[TBL] [Abstract][Full Text] [Related]
7. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.
Kozel TR; Wilson MA; Murphy JW
Infect Immun; 1991 Sep; 59(9):3101-10. PubMed ID: 1831795
[TBL] [Abstract][Full Text] [Related]
8. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.
Kozel TR; Pfrommer GS
Infect Immun; 1986 Apr; 52(1):1-5. PubMed ID: 3514450
[TBL] [Abstract][Full Text] [Related]
9. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.
Kozel TR; Levitz SM; Dromer F; Gates MA; Thorkildson P; Janbon G
Infect Immun; 2003 May; 71(5):2868-75. PubMed ID: 12704160
[TBL] [Abstract][Full Text] [Related]
10. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.
MacGill TC; MacGill RS; Casadevall A; Kozel TR
J Immunol; 2000 May; 164(9):4835-42. PubMed ID: 10779792
[TBL] [Abstract][Full Text] [Related]
11. Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.
Blackstock R; Murphy JW
Infect Immun; 1997 Oct; 65(10):4114-21. PubMed ID: 9317016
[TBL] [Abstract][Full Text] [Related]
12. Role of the capsule in phagocytosis of Cryptococcus neoformans.
Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
Rev Infect Dis; 1988; 10 Suppl 2():S436-9. PubMed ID: 3055212
[TBL] [Abstract][Full Text] [Related]
13. In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans.
Truelsen K; Young T; Kozel TR
Infect Immun; 1992 Sep; 60(9):3937-9. PubMed ID: 1500204
[TBL] [Abstract][Full Text] [Related]
14. Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.
Gates MA; Kozel TR
Infect Immun; 2006 Jun; 74(6):3096-106. PubMed ID: 16714537
[TBL] [Abstract][Full Text] [Related]
15. Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3.
Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
Infect Immun; 1988 Nov; 56(11):2794-800. PubMed ID: 3049374
[TBL] [Abstract][Full Text] [Related]
16. Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene.
Chang YC; Cherniak R; Kozel TR; Granger DL; Morris LC; Weinhold LC; Kwon-Chung KJ
Infect Immun; 1997 May; 65(5):1584-92. PubMed ID: 9125534
[TBL] [Abstract][Full Text] [Related]
17. Binding of cryptococcal polysaccharide to Cryptococcus neoformans.
Kozel TR; Hermerath CA
Infect Immun; 1984 Mar; 43(3):879-86. PubMed ID: 6365785
[TBL] [Abstract][Full Text] [Related]
18. Activation and binding of C3 by Candida albicans.
Kozel TR; Brown RR; Pfrommer GS
Infect Immun; 1987 Aug; 55(8):1890-4. PubMed ID: 3301679
[TBL] [Abstract][Full Text] [Related]
19. Accelerated decay of C3b to iC3b when C3b is bound to the Cryptococcus neoformans capsule.
Pfrommer GS; Dickens SM; Wilson MA; Young BJ; Kozel TR
Infect Immun; 1993 Oct; 61(10):4360-6. PubMed ID: 8406826
[TBL] [Abstract][Full Text] [Related]
20. Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.
Kozel TR; MacGill RS; Wall KK
Infect Immun; 1998 Apr; 66(4):1547-53. PubMed ID: 9529080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
